Clinical trials: Carbapenem-Resistant Enterobacteriaceae Infection
ECMO, Carbapenem-Resistant Enterobacteriaceae Infection
Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model
The goal of this study is to evaluate the efficacy and safety of ceftazidime-avibactam(CAZ-AVI) in the treatment of critically ill patients with carbapenem-resistant organisms(CRO) infections (including dialysis patients and…
- Trial name
- NCT06210542
- Testing
- ceftazidime avibactam
- Volunteers
- 50 people
- Sponsor
- Sichuan Provincial People's Hospital
Carbapenem-Resistant Enterobacteriaceae Infection
Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies
The first aim of this study is to explore the drug resistance mechanism of Enterobacteriaceae bacteria and to evaluate the treatment effect of ceftazidime-avibactam (CAZ-AVI) in combination with aztreonam (ATM) against…
- Trial name
- NCT05850871
- Testing
- CAZ/AVI plus Aztreonam, Conventional treatment
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Qianfoshan Hospital
Carbapenem-Resistant Enterobacteriaceae Infection
Fecal Microbiota Transplantation for Carbapenem-resistant Enterobacteriaceae
2:1, open-label, single center, randomized controlled trial comparing FMT vs. no intervention for CRE carriers,
- Trial name
- NCT04146337
- Testing
- FMT
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- Rambam Health Care Campus
Carbapenem-Resistant Enterobacteriaceae Infection
Fecal Microbiota Transplantation for Carbapenem Resistant Enterobacteriaceae
Open-label, single center, prospective interventional non-comparative study for CRE carriers.
- Trial name
- NCT04790565
- Testing
- FMT
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Rambam Health Care Campus
Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection
Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems
Enterobacterales resistant to carbapenem are cause of severe concern in hospital-acquired infections since therapeutic options are limited.
- Trial name
- ABOVE (NCT04876430)
- Testing
- Meropenem
- Where
- 2 sites in Brazil
- Volunteers
- 13 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Carbapenem-Resistant Enterobacteriaceae Infection
Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria
Patients with infections caused by carbapenem-resistant enterobacteria treated with CAZ-AVI versus patients treated with BAT are compared. The BAT group includes fosfomycin, tigecycline, gentamicin, meropenem and colistin.
- Trial name
- CAVICOR (NCT04167228)
- Testing
- Ceftazidime-Avibactam, Best Available Therapy
- Where
- 17 sites in Spain
- Volunteers
- 348 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Carbapenem-Resistant Enterobacteriaceae
Clinical Validation of the Molecular-Based GenePOC Carba Assay for the Detection and Differentiation of Carbapenemase Genes in Rectal Swab Samples.
The primary purpose of this clinical investigation is to establish the performance of the GenePOC Carba assay on the revogene. This will be achieved by comparing the test to a conventional method for detection of Carbapenemase…
- Trial name
- NCT03680898
- Testing
- Rectal swab collection
- Where
- 3 sites in United States, Canada
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Meridian Bioscience, Inc.
Carbapenem-Resistant Enterobacteriaceae Infection
Oral Capsule Faecal Microbiota Transplantation for CPE Decolonization
Double-blinded, randomised controlled trial to evaluate the clinical efficacy of a single dose of oral capsule-administered faecal microbiota transplantation (FMT) for carbapenemase-producing Enterobacteriaceae (CPE) intestinal…
- Trial name
- NCT04746222
- Testing
- Oral capsule faecal microbiota transplantation
- Volunteers
- 108 people
- Sponsor
- Tan Tock Seng Hospital
Drug Resistance, Carbapenem-Resistant Enterobacteriaceae Infection
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
The purpose of this study is to evaluate the treatment outcomes in patients with CRE infections.
- Conditions
- Drug Resistance, Carbapenem-Resistant Enterobacteriaceae Infection, Sepsis, Septic Shock
- Trial name
- NCT04516395
- Testing
- Combined antibiotic regimens, Standard antibiotic regimens
- Where
- Thailand
- Volunteers
- 102 people
- Sponsor
- Phramongkutklao College of Medicine and Hospital